Trials / Completed
CompletedNCT03142165
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986263 | 3 weekly doses of 90 mg infused intravenous administration |
| OTHER | Placebo | Placebo |
| DRUG | Diphenhydramine | 50 mg intravenous administration |
| DRUG | Famotidine | 20 mg intravenous administration |
Timeline
- Start date
- 2017-05-11
- Primary completion
- 2017-11-29
- Completion
- 2017-11-29
- First posted
- 2017-05-05
- Last updated
- 2018-01-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03142165. Inclusion in this directory is not an endorsement.